CAR-T Cell Therapy for Advanced Solid Tumors
Part of Cancer clinical trials.
This trial tests IMC001, a new type of immune cell therapy designed to fight advanced solid cancers that have stopped responding to standard treatments. The therapy uses your own immune cells engineered to recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid cancer (like gastric, breast, ovarian, colorectal, pancreatic, or biliary cancer) that has grown despite previous treatments
- Your cancer cells must test positive for a marker called EpCAM (a protein found on certain cancer cells)
- You've already tried at least two standard cancer treatments without success or couldn't tolerate them
- Your overall health is good enough (ECOG score 0–1: able to carry out normal activities with minimal limitations)
- Your blood counts and organ function (liver, kidney, heart, lungs) are within acceptable ranges
- You're between 18 and 75 years old
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new CAR-T cell therapy given as an injection for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. CAR-T therapy uses your own immune cells to target and attack cancer cells. It may be an option if you have tried other treatments and they are no longer working.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This phase 1 trial tests a new way to use your own immune cells to fight advanced solid tumors. The treatment is given directly into the tumor. It is for people who have run out of standard treatment options.
This study tests a new type of immune cell therapy that seeks out and attacks cancer cells. It is for people with advanced solid tumors who have not improved with standard treatments and whose tumors show certain markers.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Hear when a new Epithelial Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.